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Abstract Leishmaniasis is a major public health problem
and till date there are no effective vaccines available. The
control strategy relies solely on chemotherapy of the infec-
ted people. However, the present repertoire of drugs is
limited and increasing resistance towards them has posed a
major concern. The first step in drug discovery is to identify
a suitable drug target. The genome sequences of Leishmania
major and Leishmania infantum has revealed immense
amount of information and has given the opportunity to
identify novel drug targets that are unique to these parasites.
Utilization of this information in order to come up with a
candidate drug molecule requires combining all the tech-
nology and using a multi-disciplinary approach, right from
characterizing the target protein to high throughput screen-
ing of compounds. Leishmania belonging to the order ki-
netoplastidae emerges from the ancient eukaryotic lineages.
They are quite diverse from their mammalian hosts and there
are several cellular processes that we are getting to know of,
which exist distinctly in these parasites. In this review, we
discuss some of the metabolic pathways that are essential
and could be used as potential drug targets in Leishmania.
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Introduction
Leishmaniasis is a group of parasitic diseases caused by at
least 20 different species of the protozoan parasite
Leishmania. It constitutes of a wide spectrum of diseases
ranging in severity from simple cutaneous lesions to the
usually fatal visceral form. The parasite is transmitted
through the bite of sandfly to the mammalian hosts. The
disease is endemic in 88 countries and affects as many as
12 million people around the globe with an incidence of
0.5 million cases of the visceral form of the disease and
1.5–2.0 million cases of the cutaneous form of the disease,
causing extensive mortality and morbidity.
Since, effective vaccines against leishmaniasis are still
under development, the current control measures rely
solely on chemotherapy. Pentavalent antimonials are the
standard first line of treatment but emergence of resistance
towards them, has limited their usefulness. Alternative
chemotherapeutic treatments with amphotericin B and its
lipid formulation, miltefosine and paromomycin are
available but their use is limited either due to toxicity or
high cost of treatment. The current challenges in the che-
motherapy include availability of very few drugs, emer-
gence of resistance to the existing drugs, their toxicity and
lack of cost-effectiveness. Therefore, it is of utmost
importance to look for effective drugs and new drug targets
for the treatment of leishmaniasis.
There seems to be a welcome change in terms of flow of
funds for antiparasitic drug discovery. Some of the or-
ganisations like Institute of One World Health (IOWH),
Drugs for Neglected Diseases Initiative (DNDi), Bill and
Melinda Gates foundation have had a significant impact on
working towards the drug development for tropical dis-
eases. This has enabled technological advances in the field,
which includes publicly funded sequencing of the gen-
omes, thus fastening up the course towards drug develop-
ment. A major breakthrough in the field is the availability
of the complete genome sequence of various species of
Leishmania like, L. major (Ivens et al. 2005), L. infantum
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and L. braziliensis. It has provided us with enormous
information about the parasite genome for our better
understanding of these organisms. With the availability and
easily accessible genome sequences, the conventional
method of drug target identification, which was done on the
basis of the biochemical and physiological differences
between the pathogen and host, is now changing. Micro-
arrays and proteome analysis make use of the genome
sequences and has allowed us to find genes unique to the
parasite, some species-specific genes that can help us
understand the pathogen better. Several bioinformatic
approaches have also been proposed which will fasten the
pace to come up with anti-leishmanial drugs (Myler 2008).
The analysis of the complete genome sequence may sig-
nificantly contribute in drug development by revealing the
presence of novel enzymes and receptors. Furthermore, the
comparison of the parasite genome with the human genome
sequence will make the identification of genes, unique to
the parasite, easier.
Identification of drug targets
One of the characteristic features in the process of drug
development is target identification in a biological path-
way. In theory, during identification of a target in a path-
ogen, it is important that the putative target should be either
absent in the host or substantially different from the host
homolog so that it can be exploited as a drug target. Try-
panosomatids, phylogenetically, branch out quite early
from the higher eukaryotes. In fact, their cell organization
is significantly different from the mammalian cells and
thus, it is possible to find targets that are unique to these
pathogens. Secondly, the target selected should be abso-
lutely necessary for the survival of the pathogen. It is also
important to consider the stage of the life-cycle of the
pathogen in which the target gene is expressed. It is crucial
to look at the biochemical properties of the protein; it
should have a small molecule binding pocket, so that
specific inhibitors can be designed and if the target protein
is an enzyme, its inhibition should lead to loss in cell
viability. It is of high importance that the target selected
should be assayable. Inexpensive and specific assay system
should be available for high-throughput screening of mol-
ecules (Pink et al. 2005; Barrett et al. 1999).
Potential drug targets in Leishmania
Sterol biosynthetic pathway
Sterols are important components of the cell membrane
that are vital to cellular function and maintenance of cell
structure. Unlike mammalian cells, which have cholesterol
as the major membrane sterol, trypanosomatids synthesize
ergosterol and other 24-methyl sterols that are required for
their growth and viability. These sterols are absent from the
mammalian cells. Therefore, the sterol biosynthetic path-
way from Leishmania is considered to be an important drug
target (Fig. 1).
One of the enzymes that is being studied deeply is
squalene synthase (SQS) (EC 2.5.1.21) that catalyzes the
first committed step of sterol synthesis by coupling two
farnesyl molecules to form squalene. Zaragozic acids and
quinuclidines are known to inhibit SQS. Two quinuclidine
derivatives, ER-119884 and E5700 have been shown to be
potent anti-Leishmania (Fernandes Rodrigues et al. 2008)
and Trypanosoma (Urbina et al. 2004) agents. The inhibi-
tion of SQS by these compounds decreased the parasite’s
endogenous sterol levels which had an antiproliferative
effect on the parasite. In L. amazonensis, IC50 value of
ER-119884 and E5700 for promastigotes was found to be
10 and 30 nM respectively (Fernandes Rodrigues et al.
2008). Squalene is converted to 2,3-oxidosqualene by the
enzyme squalene epoxidase (EC 1.14.99.7). It converts
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Fig. 1 Sterol biosynthetic pathway in Leishmania. The pathway
shows the important steps and the enzymes involved in sterol
biosynthesis. The final product in trypanosomatids is ergosterol as
opposed to cholesterol in mammalian cells
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squalene chain to tetracyclic sterol skeleton. Terbinafine,
an allylamine, is known to inhibit squalene epoxidase. It
has been shown that terbinafine inhibits the growth of
promastigotes and intracellular amastigotes and leads to
changes in structural organization in mitochondrion (Van-
nier-Santos et al. 1995). When it is used in combination
with ketoconazole, another inhibitor of ergosterol biosyn-
thesis, the effect is synergistic. Another class of inhibitors,
bisphosphonates, inhibits the isoprenoid pathway that is
catalyzed by the enzyme farnesyl diphosphate synthase
(FPPS). They have been tested in vivo and in vitro against
the protozoan parasites (Martin et al. 2001; Docampo
and Moreno 2008). A potent inhibition of the cell growth
and suppression of the activity of isolated enzymes (from
L. major) was observed thus validating the isoprenoid
pathway as a drug target.
Another important putative target in ergosterol biosyn-
thesis is the enzyme D24,25-sterol methyltransferase (SMT)
(EC 2.1.1.41). This enzyme is only present in trypanoso-
matids and absent from the human host. Therefore, this
enzyme could be exploited as a potential drug target.
Azasterols are known to inhibit SMT in case of Candida
spp. (Ishida et al. 2009). The effect of azasterols has been
studied on Leishmania and Trypanosoma species among
the protozoan parasites. Several azasterols have been
shown to have anti-proliferative effect with their IC50s in
submicromolar to nanomolar range against L. amazonensis
(Magaraci et al. 2003; Lorente et al. 2004), signifying that
this step could be a potential chemotherapeutic target. In,
L. amazonensis, they also led to disorganization of the
mitochondrial membrane followed by intense swelling and
loss of matrix contents (Vivas et al. 1996; Rodrigues et al.
2002). Interestingly, azasterols when used in combination
with azoles act synergistically and are even more effective
suggesting that inhibiting multiple steps of this pathway,
that is, combination therapy may be used against the par-
asitic protozoa.
Glycolytic pathway
The energy metabolism of trypanosomatids solely depends
on the carbon sources available in the host. Since the
African trypanosomes lack a functional Krebs cycle, they
use glycolysis as the only source of ATP generation
(Opperdoes 1987). Seven of the glycolytic enzymes are
compartmentalized in peroxisome-like organelles, glyco-
somes, which is a unique feature of trypanosomatids
(Fig. 2). The unique compartmentalization of glycolytic
enzymes in glycosomes in Leishmania and their large
phylogenetic distance with the mammalian hosts provides
them with unique features. These features can be exploited
by designing specific inhibitors on the basis of the structure
of the parasitic enzymes. Structure based drug designing is
being employed to obtain compounds that bind to the
enzymes with high affinity. The 3-D structures are available
for some of the trypanosomatid enzymes: glyceraldehydes-
3-phosphate dehydrogenase (EC 1.2.7.6) (Vellieux et al.
1993; Kim et al. 1995), triosephosphate isomerase (5.3.1.1)
(Wierenga et al. 1991; Williams et al. 1999), phosphoglyc-
erate kinase (EC 2.7.2.10) (Bernstein et al. 1997), pyruvate
kinase (2.7.1.40) (Rigden et al. 1999), fructose-1,6-bis-
phosphate aldolase (EC 4.1.2.13) (Chudzik et al. 2000) and
glycerol-3-phosphate dehydrogenase (EC 1.1.1.8) (Suresh
et al. 2000). The differences in the 3-D structures of the
parasite and host enzymes can be used to design specific
inhibitors (Verlinde and Hol 1994).
Specific inhibitors have been designed for the glycolytic
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
based on its crystal structure. Adenosine analogs were syn-
thesized as tight binding inhibitors that occupy the pocket on
the enzyme that accommodates adenosyl moiety of NAD?
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Fig. 2 Glycolytic pathway in trypanosomatids. The figure shows the
glycolytic pathway as occurs in trypanosomatids. Seven of the
glycolytic enzymes are compartmentalized in glycosomes. The
enzymes involved in the pathway are (1) hexokinase (2) glucose-6-
phosphate isomerase (3) phosphofructokinase (4) aldolase (5) triose-
phosphate isomerase (6) glyceraldehyde-3-phosphate dehydrogenase
(7) phosphoglycerate kinase (8) glycerol-3-phosphate dehydrogenase
(9) glycerol kinase (10) phosphoglycerate mutase (11) enolase (12)
pyruvate kinase
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co-substrate. Adenosine was shown to be a poor inhibitor of
the enzyme but its analog, with substitutions at the 20 posi-
tion of ribose and N6-position of adenosine (disubstituted
analogs) resulted in enhanced inhibition of the enzyme. One
of the analogs, N6-(1-naphthalenemethyl)-20-(3-methoxy-
benzamido) adenosine inhibited growth of L. mexicana with
IC50 of 0.28 lM (Aronov et al. 1999). This indicates that it is
possible to block the energy production by synthesis of
specific inhibitors of glycolytic pathway enzymes. Since
glycolysis is the only source of energy for these parasites, it
could serve as an excellent drug target.
Purine salvage pathway
The parasitic protozoa, including Leishmania lack the
enzymes to synthesize purine nucleotides de novo, there-
fore, they have to depend upon the purine salvage system
to utilize purine bases from their mammalian hosts (Fig. 3).
Purine bases are translocated through the parasite cell
surface by nucleoside transporters.
Nucleoside transporters
They are involved in transport of nucleosides across the
membrane. Two specific transporters which have been well
documented from Leishmania are LdNT1 (present in both
promastigote and amastigotes) and LdNT2 (present in
amastigotes) (Vasudevan et al. 1998; Carter et al. 2000).
LdNT1 is responsible for transportation of adenosine and
pyrimidine nucleosides and LdNT2 transports purine
nucleosides (inosine and guanosine). LdNT1 and LdNT2
were first cloned from L. donovani by functional comple-
mentation of adenosine-pyrimidine transport deficient
mutant, TUBA5 (tubercidin resistant) and inosine-purine
transport deficient mutant FBD5 (Formycin resistant),
respectively. Two very closely related genes encoding for
pyrimidine nucleoside transporters LdNT1.1 and LdNT1.2
have been identified which show very high affinity towards
pyrimidines. It has been seen that point mutations in
LdNT1.1 and LdNT2 alter the substrate specificity and
confer resistance towards drug (Vasudevan et al. 2001;
Galazka et al. 2006). Two purine nucleobase transporters
have also been identified from L. major, LmaNT3 and
LmaNT4. LmaNT3 transports only bases hypoxanthine,
xanthine, adenosine and guanine but not nucleosides
whereas, LmaNT4 takes up only adenine at neutral pH but
at acidic pH, it can take up hypoxanthine, guanine and
xanthine as well (Ortiz et al. 2009). Its function is required
for the optimal viability of the parasite inside the acidic
phagolysosome of human macrophages. The parasitic
transporters are different from the mammalian transporters
in terms of their higher specificity towards the substrate.
The fact that there are so many pathways for the uptake of
purines; it is very difficult to target them with selective
inhibitors. But, they will remain pharmacologically
important as these transporters also uptake toxic nucleoside
analogs which are inhibitory to the cell growth.
Purine Salvage enzymes
In Leishmania, the enzyme phosphoribosyltransferase
(PRT), that converts dephosphorylated purines to nucleo-
sides monophosphates, plays an important role in salvage of
purines. Three PRTs have been identified and characterized
from Leishmania (Glew et al. 1988) namely, adenine
phosphoribosyl transferase (APRT) (EC 2.4.2.7), hypoxan-
thine-guanine phosphoribosyl transferase (HGPRT) (EC
2.4.2.8) and xanthine phosphoribosyl transferase (XPRT)
(2.4.2.22). HGPRT converts hypoxanthine to inosine
monophosphate and guanine to guanine monophosphate.
Various inhibitors have been designed to target HGPRT due
to its difference in substrate specificity with the host enzyme.
The most common inhibitor used is allopurinol that is
phosphorylated by HGPRT and incorporated into nucleic
acid thus leading to selective death of the parasite (Marr
1983; Fish et al. 1985). Allopurinol has been shown to be
effective against cutaneous (Martinez and Marr 1992) and
visceral Leishmaniasis (Kager et al. 1981). Allopurinol
when used with other anti-leishmanial drugs was found to be
even more effective. Phthalic anhydride derivative (struc-
tural analogs of purine bases), TF1 and phthalimide deriv-
ative, TF2, have also been shown to be effective against
Leishmania (Somoza et al. 1998). However, it has been
found that PRTs are not essential for parasite’s survival. This
is possible since there are various alternative purine salvage
pathways present in Leishmania. Therefore, it is necessary to
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Fig. 3 Purine salvage pathway of Leishmania species. The enzymes
involved in salvage of purines are (1) phosphoribosyltransferase (2)
adenine deaminase (3) guanine deaminase (4) adenosine deaminase
(5) nucleoside kinase (6) nucleotidase (7) AMP deaminase (8) AMP
kinase (9) GMP kinase (10) IMP dehydrogenase (11) GMP synthetase
(12) GMP reductase. AMP adenosine monophosphate; ADP adeno-
sine diphosphate; IMP inosine monophosphate; XMP xanthine
monophosphate; GMP guanosine monophosphate; GDP guanosine
diphosphate
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target more than one enzyme at a time to come up with an
anti-leishmanial chemotherapy.
GPI biosynthetic pathway as drug target
Glycosylphosphatidylinositol (GPI) glycolipids are major
cell surface constituents in the Leishmania parasites that
act as anchor to various cell surface glycoproteins. The cell
surface of the promastigotes is coated by glycocalyx which
consists of GPI anchored glycoproteins, GPI-anchored
lipophosphoglycan (LPG) and a family of free GPIs, called
as glycoinositolphospholipids (GIPLs), in high densities
(Fig. 4). They protect the parasite from the alternate
complement pathway and external hydrolases. LPG is
essential for the infectivity of L. major promastigotes in
both the mammalian and insect hosts (Spath et al. 2000;
Sacks et al. 2000). The core glycan unit of all protein
linked GPIs is conserved and has the structure (Ethanol-
amine-P-Mana1-2Mana1-6Mana1-4GlcNH2), which is
linked to the 6-position of D-myo-inositol ring of phos-
phatidylinositol (PI) (Ferguson et al. 1999). GPI anchors
are synthesized in a step-wise manner in endoplasmic
reticulum membrane and then attached to the nascent
proteins. These GPI anchored proteins are then transferred
to the plasma membrane via the secretory pathway. GPI
biosynthesis is essential for bloodstream form T. brucei
parasites and has been validated as a chemotherapeutic
target (Ferguson 2000).
The first step in GPI biosynthesis is the formation of
GlcNAc-PI, by the transfer of N-acetylglucosamine
(GlcNAc) from UDP-GlcNAc to PI. The reaction is cata-
lyzed by the protein complex, GPI-N-acetylglucosaminyl-
transferase (GPI-GnT). Then, GlcNAc-PI is de-N-acetylated
to form GlcN-PI, catalyzed by GlcNAc-PI-de-N-acetylase.
This is an essential step for all GPI biosynthetic pathways.
Trypanosomal enzyme has been shown to be zinc metallo-
enzyme (Urbaniak et al. 2005). The enzymes from T. brucei
(Sharma et al. 1997) and L. major (Smith et al. 1997) showed
narrow substrate specificity than the human homolog in
vitro. Substrate specificity was determined using substrate
analogs of GlcNAc-PI. The substrate analog GlcNR-PI
where R is an acyl group larger than propionyl group were
not de-N-acetylated by the enzyme but when this group was
substituted with benzoyl group, the analog was shown to
inhibit the parasitic enzyme and not the human counterpart.
The difference in the substrate specificities of the two
enzymes has been exploited and two synthetic GlcNAc-PI
analogs, GlcNCONH2-b-PI and GlcNCONH2-(2-O-octyl)-
PI were shown to be T. brucei specific suicide inhibitors
(Smith et al. 2001).
Differences between the parasitic and mammalian GPI
biosynthetic pathways occur from GlcN-PI onwards,
including the timing of inositol acylation and deacylation.
The next step in GPI biosynthesis in case of parasites is
mannosylation of GlcN-PI which is followed by inositol
acylation, whereas, in yeast and human, inositol acylation
is a pre-requisite for mannosylation. The trimannosyl core
of GPI anchors is added stepwise and involves three dis-
tinct mannosyl transferases (MT). Mannosyltransferase III
(MTIII) has been found to be substrate specific. There is a
difference in the structure of the substrates for the mam-
malian and the trypanosomal MTIII which suggests that
species-specific inhibition can be achieved by synthesizing
small molecule inhibitors (Urbaniak et al. 2008). The
mannose donor for all GPI-mannosyl transferases is doli-
chol-P-mannose (Dol-P-Man). Dol-P-Man is synthesized
by the enzyme Dol-P-Man synthase which can be inhibited
by the addition of lipopeptide antibiotic amphomycin
which forms a complex with Dol-P, and thereby inhibiting
GPI biosynthesis. The enzymes MT require divalent cat-
ions for their function and can be inhibited in vitro by
metal chelators like EDTA. GlcN-PI analog, GlcN-
(2-O-hexadecyl)PI inhibits specifically the first mannosyl-
transferase in T. brucei in a competitive manner.
The next step is the acylation of inositol. In T. brucei, it
can be inhibited in vivo as well as in vitro using a serine
esterase inhibitor phenylmethylsulphonyl fluoride (PMSF)
leading to accumulation of the Man3-GlcN-PI intermediate
in T. brucei. This inhibition of trypanosomal inositol
acylation was also observed in vitro with either GlcN-
(2-O-methyl)-PI or GlcN-(2-O-octyl)-PI (Smith et al.
1999). The final step of synthesis of GPI core glycan
structure, involves transfer of ethanolamine phosphate to
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Fig. 4 Structure of the major GPI classes synthesized by L. mexicana
promastigotes. These glycolipids act as anchors for major cell surface
proteins (GPI anchored proteins), surface lipophosphoglycans (LPGs)
and free glycolipids (GIPLs). M2–4 denotes GPIs with the structures
Man2–4GlcN-PI; EP denotes the presence of an EtN-P cap or side
chain; and the prefix i denotes the presence of an a1-3-linked
mannose in the core structure
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6th position of the third mannose. Since, PMSF inhibits the
inositol acylation of the intermediate Man3-GlcN-PI to
form Man3-GlcN-(acyl)-PI in T. brucei, the addition of
ethanolamine phosphate is prevented (Guther et al. 1994).
The mammalian enzyme is not inhibited by PMSF. This
selective inhibition implies significant differences in the
structure of the enzymes which can be exploited for
designing specific inhibitors.
After the completion of GPI anchor synthesis, lipid
remodeling takes place which involves exchange of fatty
acid components with other fatty acid of the lipid moiety or
the whole lipid component. T. brucei contains myristate as
the major lipid component in its GPI-anchored variable
surface glycoproteins. The major product of fatty acid
biosynthesis in T. brucei is myristate which is required to
be incorporated into GPI anchors and therefore, this path-
way can be targeted in T. brucei. Thiolactomycin, an
inhibitor of fatty acid synthesis leads to death of parasites.
Myristate specific remodeling has been reported for
Leishmania GPIs also. Incorporation of myristate analogs
into the GPI anchor is toxic to trypanosomes. Therefore,
the enzymes of fatty acid remodeling are possible targets
for anti-trypanosome chemotherapy. The mature GPI pre-
cursor is transferred to the protein by transamidation
reaction by a multimeric protein complex, where, COOH
terminal signal peptide is replaced by the formation of
amide linkage to amino group of ethanolamine phosphate
linked to the third mannose of GPI anchor. The protein
components differ in different species, suggesting that
these differences between the parasite and mammalian
enzymes can be exploited for drug designing.
Protein kinases as drug targets
Cyclin dependent kinases (CDKs) are known to play a cru-
cial role in cell division. They have been found to be
abnormally regulated in cancer cells and have therefore
drawn attention as drug targets. In Leishmania, the cdc-2
related kinase (CRK) family has attracted attention as
potential drug targets. They are homologs of CDKs and are
thought to be essential for cell cycle progression. Two
putative CDKs in L. mexicana, LmexCRK1 and LmexCRK3
(Hassan et al. 2001) have been found to be essential to the
promastigotes form of the parasite. Attempts to generate null
mutants of CRK3 resulted in change in ploidy of the parasite
(Hassan et al. 2001). CRK3 is found to be active throughout
the life cycle in L. mexicana (Grant et al. 1998). CRK3 from
L. major was able to complement a temperature sensitive
cdc-2 mutant in S. pombe. Inhibitors of CRK3, inhibited the
growth and replication of L. donovani amastigotes in peri-
toneal macrophages. These compounds also led to aberrant
DNA content and abnormal morphology of the cells as
determined by the flow cytometry (Grant et al. 2004).
MAP kinases
Mitogen-activated Protein (MAP) kinases are mediators of
signal transduction and important regulators of cell differ-
entiation and cell proliferation in eukaryotic cells. So far, ten
MAP kinases have been identified in L. mexicana, of which
LmxMKK, LmxMPK and LmxMPK9 (Wiese 1998; Wiese
et al. 2003; Bengs et al. 2005) have been studied intensely.
Null mutants of both LmxMKK and LmxMPK9 are viable
both in amastigote and promastigote stages of the life cycle
and therefore, neither of them can be exploited as drug tar-
gets. However, null mutants of LmxMPK, has the ability to
infect peritoneal macrophages and differentiate into am-
astigotes, but are unable to proliferate within the parasi-
tophorous vacuole. This phenotype was reverted back by the
reintroduction of LmxMPK to the mutant (Wiese 1998).
Therefore, LmxMPK is found to be essential for the growth
of the more relevant amastigote form and can be used as a
drug target.
Proteinases as drug targets
Proteinases are of four main types- cysteine, serine,
aspartate and metallo-enzymes. The name is given on the
basis of the residue present in the active site. In case of
parasitic protozoa, the most identified and characterized are
the cysteine proteinases (CPs), which are homologous to
mammalian cathepsins. CPs have attracted attention as
potential drug targets because of their role in host cell–
parasite interaction, as putative virulence factor, and being
structurally different from the mammalian homolog.
Analysis of L. major genome database revealed that there
are genes encoding for as many as 65 CPs. CPs are further
divided into different types. CPA and CPB are both
cathepsin L-like proteinases in terms of amino acid
sequence. CPC is cathepsin B-like proteinases. CPA, CPB
and CPC are involved in host-parasite interaction as deter-
mined by gene replacement studies in L. mexicana.
L. mexicana deficient in the multicopy CPB gene array
(Dcpb) have reduced virulence with poor lesion growth in
BALB/c mice (Alexander et al. 1998). A natural inhibitor of
CP (ICP) from L. mexicana has been characterized and has
been shown to be a potent inhibitor of CPB. BALB/c mice
infected with mutants overexpressing ICP were able to
resolve the infection faster (Bryson et al. 2009). In another
study, T. brucei infected mice were treated with cysteine
proteinase inhibitor, carbobenzoxy-phenylalanyl-alanine-
diazomethyl ketone (Z-Phe-Ala-CHN2). It led to alteration
in cell morphology and was lethal to the cultured parasites
(Scory et al. 2007). These studies provide evidence of the
therapeutic potential of the inhibitor of cysteine proteinases.
In T. brucei, RNAi studies have shown a cathepsin B like
protease tbcatB, as a key target (Mackey et al. 2004).
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Parasites containing single copy of tbcatb show enlargement
of lysosome and decreased degradation of endocytosed host
proteins (O’Brien et al. 2008). The CPs are also of interest
because of their structural differences with the mammalian
CPs. The protein tbcatB has been crystallized and its struc-
ture confirms an occluding loop which is important for
substrate binding (Kerr et al. 2010). This loop creates a
larger prime side pocket in active site cleft than is found in
mammalian cathepsin B. The difference in the structure of
the proteins may be utilized for design of inhibitors.
Folate biosynthesis
Folate pathway has been of interest as a drug target and has
been used in anti-cancer and anti-malarial chemotherapy.
Folates are important cofactors used in a variety of meta-
bolic pathways like DNA and RNA synthesis and amino acid
metabolism. Since they are essential for growth, the
enzymes involved in their synthesis have been of interest as
drug targets, particularly, thymidylate synthase (TS) (EC
2.1.1.45) and dihydrofolate reductase (DHFR) (EC 1.5.1.3)
which is responsible for converting dihydrofolate to tetra-
hydrofolate, an important cofactor in the synthesis of thy-
mine. TS and DHFR catalyze sequential reactions to
synthesize dTMP (Fig. 5a). Both the enzymes have been
studied intensively and used as targets for chemotherapy.
Interestingly, TS and DHFR exist on a single polypeptide in
case of trypanosomatids, with DHFR domain on amino
terminus and TS domain on carboxy terminus. TS-DHFR
has been characterized from L. major. The classic inhibitors
of DHFR were found to be ineffective against Leishmania
(Neal and Croft 1984). An answer to that came from the
genetic analysis which showed amplification of the gene
pteridine reductase (PTR1) (1.5.1.33) in some of the mutants
in Leishmania which were resistant to methotrexate (an
inhibitor of DHFR-TS) (Nare et al. 1997). PTR1 can reduce
both pterins and folates (Fig. 5b) and is much less suscep-
tible to inhibition by anti-folates, as revealed by structural
studies, targeted against DHFR. Therefore, it can act as a
bypass system for DHFR-TS. A number of compounds have
been screened against PTR1 in L. major (Hardy et al. 1997).
Several compounds were found to be inhibiting both DHFR-
TS and PTR1. However, only four such compounds were
identified that inhibited both the enzymes and the growth of
the parasite potently. This indicates that an inhibitor is
required that targets both the enzymes simultaneously or two
compounds that can be used in combination specifically
inhibiting both the enzymes.
Glyoxalase system
The Glyoxalase system functions to detoxify the cell
by removal of toxic and mutagenic intermediate,
methylglyoxal, which is mainly formed as a by-product of
glycolysis. It is also formed during threonine catabolism
and acetone oxidation (Cooper 1984; Vickers et al. 2004).
The glyoxalase system comprises of two enzymes viz.
glyoxalase I (lactoyl glutathione lyase) (EC 4.4.1.5)
and Glyoxalase II (hydroxyacyl glutathione hydroxylase)
(EC 3.1.2.6) and uses glutathione as a cofactor. However,
trypanosomatids rely on a trypanothione dependent
glyoxalase system (Fig. 6) which is unique to these
parasites, where glyoxalase I catalyzes the formation of
S-D-lactoyltrypanothione from hemithioacetal. Hemi-
thioacetal is formed non-enzymatically from methylgly-
oxal and reduced trypanothione. S-D-lactoyltrypanothione
is further hydrolysed to D-lactate regenerating trypano-
thione by glyoxalase II (Vickers et al. 2004).
Glyoxalase I has been characterized from L. donovani
(Padmanabhan et al. 2005) and L. major (Vickers et al.
2004). The enzyme is highly substrate specific as it
depends entirely on trypanothione as substrate, instead of
glutathione as in their mammalian hosts. Superposition of
L. donovani glyoxalase I with crystal structure of E. coli
glyoxalase I showed that its substrate binding loop is
smaller in comparison to glutathione utilizing enzymes and
is devoid of positively charged residues, as observed for
human and E. coli homolog (Padmanabhan et al. 2005).
L. donovani glyoxalase I has been found to be an essential
gene in the parasite (Chauhan and Madhubala 2009).
Glyoxalase II was first identified from T. brucei. It is
expressed in both procyclic and bloodstream forms of
T. brucei (Irsch and Krauth-Siegel 2004). Glyoxalase II has
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Fig. 5 Folate synthesis pathway. a The figure shows the synthesis of
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converts it into dihydrofolate. It is then converted back to tetrahy-
drofolate by the enzyme DHFR. b The schematic diagram shows that
the enzyme pteridine reductase (PTR1) can reduce both pterins and
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also been characterized from L. donovani (Padmanabhan
et al. 2006). Sequence comparison shows that it lacks the
basic residues in its active site which are conserved in
human homolog. These residues are important for binding
to glutathione. The substrate for L. donovani Glyoxalase II
is thioester of trypanothione, which is positively charged.
Therefore, it cannot be accommodated in the active site of
the human enzyme. This observation strongly suggests that
the parasitic enzymes are highly substrate specific. There-
fore, trypanothione-dependent glyoxalase pathway has
drawn attention for additional biochemical and genetic
investigation as a possible target for rational drug design.
Trypanothione pathway
As discussed above, trypanothione (bis-(glutathionyl)
spermidine) is a key molecule against oxidative stress in
Trypanosoma and Leishmania. It is not only unique to the
parasite but is also crucial in maintaining the cellular redox
potential and thus is essential for parasite survival. Try-
panothione synthesis is catalyzed by two enzymes, namely,
trypanothione synthetase (TS) (EC 6.3.1.9) and trypano-
thione reductase (TR) (EC 1.8.1.12). TS catalyzes trypa-
nothione synthesis from two molecules of glutathione and
spermidine (Fig. 7a). Trypanothione is then maintained in
its reduced form by the enzyme TR in the presence of
NADPH (Fairlamb et al. 1985). Reduced trypanothione in
turn reduces tryparedoxin (TX) followed by reduction of
tryparedoxin recycling enzyme tryparedoxin peroxidase
(TP) (EC 1.11.1.15) (Fig. 7b). Since, this is the only
pathway that is crucially involved in regulating oxidative
stress in these parasites; therefore, trypanothione pathway
has become the focus of anti-trypanosomatid drug discovery.
Both TR and TP have been shown to be important drug tar-
gets. Null mutants of TR show attenuated infectivity and
decreased capacity to survive within intracellular macro-
phages (Dumas et al. 1997). TR is similar in sequence and
structure to its human counterpart, glutathione reductase.
However, the active site of TR shows five non conservative
changes in its active site, giving it overall negative charge
which can accommodate trypanothione disulfide and gives
the enzyme its specificity towards its substrate (Zhang et al.
1996). This difference in substrate specificities has allowed
synthesis of specific inhibitors against the parasite. Many lead
compounds that inhibit TR have been identified including,
polyamine derivatives, tricyclics and aminodiphenyl sulp-
hides (Werbovetz 2000). Trypanothione pathway thus, pro-
vides a promising drug target in trypanosomatids.
Topoisomerases as drug targets
DNA topoisomerases are ubiquitous enzymes that play an
important role in many essential processes like DNA rep-
lication, transcription, recombination and repair. They are
broadly classified as type I and type II topoisomerases that
cleave single stranded and double stranded DNA, respec-
tively. DNA topoisomerases have been used as chemo-
therapeutic targets for anti-bacterial and anti-parasitic
diseases. Type I topoisomerase (EC 5.99.1.2) have been
characterized from L. donovani and T. cruzi. The enzyme
was found to be independent of ATP (Das et al. 2004a).
L. donovani topoisomerase I was found to be present in
both kinetoplast and nucleus (Das et al. 2004b). Inhibitors
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of type I topoisomerase include anti-leishmanial com-
pounds such as sodium stibogluconate and urea stibamine.
Camptothecin, a plant alkaloid and a known inhibitor of
eukaryotic topoisomerase I, was found to be inhibitory to
T. brucei, T. cruzi and L. donovani. Analogs of campto-
thecin have also been screened against trypanosomes and
the structural motifs have been identified which specifically
inhibit the parasitic topoisomerase I with more potency
(Bodley et al. 1995). Topoisomerase II (EC 5.99.1.3) has
been identified from T. brucei (Strauss and Wang 1990),
T. cruzi (Fragoso and Goldenberg 1992) and L. donovani
(Das et al. 2001). Interestingly, the topoisomerase II from
T. brucei and L. donovani were found to contain both ATP
dependent and independent activities. Topoisomerase II
inhibitor, 9-anilinoacridine (used as anti-tumor agent) and
other acridine derivatives inhibited Leishmania and
Trypanosoma strongly (Figgitt et al. 1992). Dihydrobetu-
linic acid (DHBA), a derivative of betulinic acid (which is
a pentacyclic triterpenoid) has been reported to be active
against both Topoisomerase I and topoisomerase II from
L. donovani (Chowdhury et al. 2003). Three isoflavanoids,
8-prenylmucronulatol, lyasperin H and smiranicin have
been found to be anti-leishmanial and this activity has been
correlated to kDNA linearization and inhibition of topoi-
somerase II (Salem and Werbovetz 2005). However, their
use is limited due to their low cell toxicity. The structure of
L. donovani topoisomerase I bound to nicked DNA cap-
tured as a vanadate complex has been elucidated (Davies
et al. 2006). The structural analysis of these enzymes will
give us an insight into their catalytic mechanisms and will
also enable us to design specific inhibitors against
Leishmania.
Hypusine pathway
Hypusine (Ne-(4-amino-2-hydroxybutyl) lysine), an unu-
sual amino acid derived from the polyamine spermidine, is
present in all the eukaryotes. Its name is derived from its
two structural components, hydroxyputrescine and lysine
(Shiba et al. 1971). It is synthesized as a result of post-
translational modification occurring exclusively on one
cellular protein, eukaryotic initiation factor 5A (eIF5A). It
is formed in two enzymatic steps (Park et al. 1982) (Fig. 8).
The first step is catalyzed by the enzyme deoxyhypusine
synthase (DHS) (EC 2.5.1.46) which catalyses the NAD?
dependent transfer of the 4-aminobutyl moiety of spermi-
dine to a specific lysine residue of the eIF5A precursor
protein to form an intermediate, deoxyhypusine (Chen and
Dou 1988; Murphey and Gerner 1987). This intermediate is
subsequently hydroxylated by the enzyme deoxyhypusine
hydroxylase (DOHH) (EC 1.14.99.29) (Abbruzzese et al.
1986) which completes the synthesis of hypusine and
maturation of eIF5A.
Hypusination of eIF5A is necessary for its function and
cell viability. Disruption of two eIF5A genes (TIF51A and
TIF51B) (Schnier et al. 1991) and DHS gene (Park et al.
1998) from Saccharomyces cerevisiae produces a lethal
phenotype. Inhibitors of hypusine biosynthetic enzymes,
DHS (spermidine analogs) and DOHH (metal chelators)
have been shown to exert anti-proliferative effects in
mammalian cells including cancer cell lines (Park et al.
1994; Nishimura et al. 2005). Recently, we have shown
that hypusine biosynthesis occurs in Leishmania donovani.
Interestingly, Leishmania has two genes containing DHS
domains viz., DHS-like gene (DHSL20) and DHS34 gene,
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of which only DHS34 protein was found to contain func-
tional activity in vitro. Null mutants of DHS34 gene could
not be generated implying that the gene is essential to the
parasite’s survival (Chawla et al. 2010). Structural mod-
eling of DHS34 protein showed that one of the NAD?
binding domains lies in a 225-amino acid long insertion
present in DHS34 protein as compared to the human
homolog. The recombinant DHS34 remained uninhibited
by most potent inhibitors of the human enzyme like GC7
and other spermidine analogs, indicating that there is a
difference between the spermidine binding sites of both the
enzymes which could be exploited to design inhibitors.
Concluding remarks
Over the last decade, there has been a burst of activity
towards the development of efficient drugs against the
parasitic diseases including leishmaniasis. Target based
drug discovery is being employed rather than the random
screening of compounds, as the former approach produces
more specific results. Many technological advances have
been made, which has led to an extensive search for
identification of novel drug targets. In the post-genomic
era, a lot of proteins, enzymes, metabolites and pathways
have been identified in trypanosomatids which are unique
to these pathogens and could be exploited as drug targets.
However, as outlined in the review, it is very critical to
identify the suitable proteins or other metabolites to be
used as drug targets. Several biochemical pathways have
been discussed here which have been identified as targets
for anti-leishmanial drug discovery. Glycolytic pathway,
sterol biosynthesis and trypanothione pathway are quite
distinct in Leishmania as compared to its mammalian host
and therefore have been of interest for drug discovery. We
have also identified a novel hypusine biosynthetic pathway
in L. donovani. The enzyme DHS was found to be essential
to the parasite and structurally different from the human
homolog. The identified drug targets can then be used for
high throughput screening with chemical libraries for
which development of cheap and efficient assay system is
required. Furthermore, refinement in the structure of the
available compounds is required to synthesise more spe-
cific and effective inhibitors for these metabolic pathways.
We have to combine all the technology and the information
available with us to come up with more drug targets and
eventually, with much needed new drugs to combat this
deadly disease.
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